# Tadalafil: effects on blood pressure and arterial stiffness in systolic hypertension

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
30/09/2004	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	[] Individual participant data
10/09/2008	Circulatory System	[] Record updated in last year

#### Plain English summary of protocol

Not provided at time of registration

# Contact information

## Type(s)

Scientific

#### Contact name

Dr Ian B Wilkinson

#### Contact details

Clinical Pharmacology Unit Level 3, ACCI Box 110 Addenbrooke's NHS Trust Cambridge United Kingdom CB2 2QQ +44 (0)1223 336806 ibw20@cam.ac.uk

# Additional identifiers

Protocol serial number N0544129338

# Study information

Scientific Title

#### Study objectives

Does the selective phosphodiesterase-5 inhibitor tadalafil reduce arterial stiffness and blood pressure in systolic hypertension?

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Hypertension

#### **Interventions**

The project will assess the effects of a single dose of the selective phosphodiesterase-5 inhibitor tadalafil on arterial stiffness and blood pressure in patients with systolic hypertension. Subjects will visit the Vascular Research Clinics for a screening visit and two study visits and will receive either placebo or tadalafil on each study visit. Measurements of blood pressure and arterial stiffness will be made at baseline and at hourly intervals for four hours following administration of the drug or placebo.

## Intervention Type

Drug

#### Phase

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Tadalafil

## Primary outcome(s)

Not provided at time of registration

# Key secondary outcome(s))

Not provided at time of registration

# Completion date

10/08/2006

# **Eligibility**

#### Key inclusion criteria

15 subjects over 18 years

## Participant type(s)

Patient

## Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

#### Sex

All

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

11/08/2003

#### Date of final enrolment

10/08/2006

# Locations

#### Countries of recruitment

**United Kingdom** 

England

## Study participating centre Clinical Pharmacology Unit

Cambridge United Kingdom CB2 2QQ

# Sponsor information

## Organisation

Department of Health

# Funder(s)

## Funder type

Government

#### Funder Name

Cambridge Consortium - Addenbrooke's (UK)

# **Results and Publications**

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes